Compound for delivering small nucleic acid to brain cells and application thereof
By developing compounds with levodopa targets and small nucleic acid conjugates, the problems of dopamine neuron death and poor drug efficacy in Parkinson's disease treatment were solved, and efficient delivery and gene targeting were achieved in brain cells. Treatment provides safer and more effective treatment options.
Patent Information
- Application Number
- CN202410995257.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-24
AI Technical Summary
Existing Parkinson's disease treatment drugs cannot effectively prevent the death of dopamine neurons and pathological deterioration, and long-term use can easily cause adverse reactions, and small nucleic acid drugs are difficult to effectively deliver to brain cells, resulting in poor drug effectiveness.
Develop a conjugate formed by chemical coupling of a compound with a levodopa target with a small nucleic acid that can enter brain cells without an exogenous transfection agent, increase dopamine concentration in the brain, and target inhibitory correlations Neurological disease gene expression.
It is achieved to increase the dopamine concentration in the brain without causing adverse reactions, alleviate Parkinson's symptoms, and improve or resolve neurological diseases at the genetic level, providing a longer duration of efficacy.
Smart Images

Figure CN118930469A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of small nucleic acid delivery, and in particular relates to a compound for delivering small nucleic acid to brain cells and an application thereof. Background Art
[0002] There are three main dopamine nervous system-related pathways in the human brain. The first is the nigrostriatal pathway, which is mainly responsible for the regulation and control of autonomous movement. The second is the midbrain cortical pathway from the ventral tegmental area to the prefrontal cortex. The dopamine released by this pathway is mainly related to cognition and is responsible for making decisions. The third is a small amount of dopamine secreted by the ventral tegmental area that directly reaches the nearby nucleus accumbens, forming the midbrain limbic pathway, which is also called the "reward pathway."
[0003] Once the dopamine nervous system is impaired, some related neurological diseases will occur. For example, in the nigrostriatal pathway, the reduction or death of neuronal cells will cause a significant decrease in dopamine release, further leading to Parkinson's disease (PD), the second most common neurodegenerative disease after Alzheimer's disease. The incidence of PD increases with age, and it is estimated that by 2030, there will be 10 million PD patients worldwide.
[0004] At present, the drugs for treating PD are mainly dopamine replacement therapy (such as levodopa, COMT inhibitors, MAO-B inhibitors, dopamine receptor agonists, etc.). Although they can relieve the symptoms of patients, they cannot prevent the progressive death of dopamine neurons, delay or block the pathological deterioration of PD, and long-term use can easily cause adverse reactions such as dyskinesia. Therefore, the clinical treatment of Parkinson's disease urgently needs new safe and effective drugs.
[0005] Levodopa is a precursor of dopamine. It can enter the brain through the blood-brain barrier and then be converted into dopamine, thereby increasing the dopamine content in the brain and improving the symptoms of Parkinson's patients. It was approved by the FDA for the treatment of Parkinson's disease in 1970 and is still the gold standard for the treatment of Parkinson's disease. However, after levodopa enters the human body, more than 95% is converted into dopamine by dopa decarboxylase in the peripheral system, and only 1% can enter the human brain and be used. Therefore, the current popular treatment method is the combined use of levodopa and dopa decarboxylase inhibitors (such as benserazide and carbidopa, etc.) to increase the content of levodopa in the central nervous system.
[0006] At present, clinical treatment of PD drugs, such as levodopa, dopamine receptor agonists, monoamine oxidase type B (MAO-B) inhibitors, and catechol-O-methyltransferase inhibitors, have short half-lives and poor duration of efficacy. Patients need to take medication frequently and for a long period of time, which brings unfavorable factors to patient compliance.
[0007] Small nucleic acid drugs have the advantages of good efficacy and long-lasting efficacy. This PCSK9-targeted nucleic acid interference inhibitor only requires two injections per year to restore the patient's low-density lipoprotein (LDL) metabolism to normal levels, while the same target monoclonal antibody inhibitor requires two injections per month. Recent clinical results of Alnylam's treatment of hypertension showed that a single dose of small nucleic acid drugs can permanently reduce blood pressure and support a dosing regimen every six months. The development of targeted drugs to prevent or treat neurological diseases will be able to improve or even solve neurological diseases at the genetic level, but the first problem to be solved is how to effectively deliver small nucleic acids to brain cells (especially neurons). Summary of the invention
[0008] The object of the present invention is to provide a novel compound for delivering small nucleic acids to brain cells, which is capable of delivering small nucleic acids to brain cells.
[0009] Another object of the present invention is to provide a conjugate formed by chemically coupling a small nucleic acid capable of targetedly inhibiting the expression of a target site associated with a nervous system disease and the above-mentioned compound for delivering the small nucleic acid to brain cells.
[0010] Another object of the present invention is to provide a targeted drug for preventing or treating nervous system diseases.
[0011] In order to achieve the above object, the technical solution adopted by the present invention is:
[0012] The first aspect of the present invention provides a compound for delivering small nucleic acids to brain cells, the structural formula of the compound is: Z is C or O, X is C, N, O or S, Y is C or O, m is 1, 2 or 3, and n is 1, 2 or 3.
[0013] Furthermore, the X is O or C, the Y is C, and the Z is C.
[0014] Furthermore, the m is 1 or 2, and the n is 1 or 2.
[0015] According to some specific embodiments, the compound for delivering small nucleic acids to brain cells is:
[0016]
[0017] The conjugate formed by coupling the compound of the present invention with small nucleic acid can enter brain cells without other exogenous transfection agents, and thus can be used as a new delivery carrier for delivering small nucleic acids to brain cells.
[0018] Specifically, the compounds of the present invention can help small nucleic acids reach the brain and be expressed in brain cells. According to relevant studies, the conjugates formed by the compound of the present invention and small nucleic acids can deliver small nucleic acids into neuronal cells, which is expected to achieve the purpose of treating related diseases caused by the reduction or death of dopamine neuronal cells, such as Parkinson's disease.
[0019] The second aspect of the present invention provides the use of the above-mentioned compound for delivering small nucleic acids to brain cells in the preparation of targeted drugs for preventing or treating nervous system diseases.
[0020] Furthermore, the nervous system disease includes Parkinson's disease.
[0021] Furthermore, the active ingredients of the targeted drug include small nucleic acids, which are small nucleic acids that can target and inhibit the expression of targets related to nervous system diseases, and the compound for delivering small nucleic acids to brain cells can deliver the small nucleic acids to brain cells.
[0022] The third aspect of the present invention provides a conjugate, wherein the conjugate is formed by chemically coupling a small nucleic acid capable of targeted inhibition of expression of a target site associated with a nervous system disease and the above-mentioned compound for delivering the small nucleic acid to brain cells.
[0023] Furthermore, the preparation method of the conjugate is: mixing the small nucleic acid sequence containing thiol modification with the compound for delivering small nucleic acid to brain cells as described above at 20-30° C. to obtain the conjugate.
[0024] According to some embodiments, the small nucleic acid is siRNA, and the 5' end or 3' end of the sense strand of the siRNA is mixed with the compound described above for delivering small nucleic acids to brain cells to obtain a conjugate, and then the sense strand and the antisense strand are mixed in equimolar amounts to form a conjugate containing a L-DOPA structure and siRNA.
[0025] According to some embodiments, the nervous system disease-related targets include one or more of CDK14, SNCA or LRRK2.
[0026] Furthermore, the small nucleic acid includes one or more of a messenger nucleic acid, a small interfering nucleic acid, a micronucleic acid, a small activating nucleic acid, an antisense oligonucleotide or an aptamer.
[0027] The fourth aspect of the present invention provides a targeted drug for preventing or treating nervous system diseases, wherein the targeted drug comprises the conjugate described above and optionally comprises a pharmaceutically acceptable excipient.
[0028] Furthermore, the auxiliary materials include excipients and the like.
[0029] Furthermore, the targeted drug is a lyophilized powder or an injection.
[0030] Furthermore, the target of the targeted drug is a mammal, preferably a human.
[0031] Furthermore, the targeted drug is administered by intramuscular injection, intravenous injection, etc.
[0032] The present invention has at least the following beneficial effects:
[0033] The present invention develops a compound capable of delivering small nucleic acids into brain cells. The compound carries a levodopa target head and has a special linker structure. The compound can form a conjugate by coupling with a small nucleic acid through its linker structure, which can enter brain cells without using other exogenous transfection agents, thereby hopefully achieving, on the one hand, that the levodopa entering the brain is converted into dopamine by dopa decarboxylase, thereby increasing the dopamine concentration in the brain, which is used to alleviate the symptoms of neurological diseases (such as Parkinson's disease); on the other hand, small nucleic acids targeting targets related to neurological diseases (such as Parkinson's disease-related targets CDK14, SNCA, LRRK2, etc.) can alleviate or even resolve neurological diseases at the gene level, bringing greater benefits to patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 The biological activity test results of the conjugate (NDS012-01) of Example 1;
[0035] Figure 2 is the hydrogen nuclear magnetic resonance spectrum of compound 4 in Example 2;
[0036] Figure 3 is the hydrogen nuclear magnetic resonance spectrum of compound 5 (L-DOPA-Mal-2) in Example 2;
[0037] Figure 4 The biological activities of the conjugate of Example 2 (NDS012-02) and the conjugate of Example 1 (NDS012-01) are compared;
[0038] Figure 5 is the hydrogen nuclear magnetic resonance spectrum of compound 2 in comparative example 1;
[0039] Figure 6 is the hydrogen nuclear magnetic resonance spectrum of compound 3 (L-DOPA-Mal-3) in Comparative Example 1;
[0040] Figure 7 The biological activities of the conjugate of comparative example 1 (NDS012-03) and the conjugate of example 1 (NDS012-01) are compared. DETAILED DESCRIPTION
[0041] In order to develop targeted drugs for preventing or treating neurological diseases, the first problem to be solved is to provide a delivery carrier that can effectively deliver small nucleic acids to brain cells. To this end, the inventors of the present application have developed and synthesized a compound with a levodopa target head (L-DOPA-Mal) after long-term research and a large number of experimental verifications. The conjugate obtained by chemically coupling it with a small nucleic acid can enter human neuroepithelioma cells without other exogenous transfection agents, thereby hopefully achieving, on the one hand, the levodopa entering the brain is converted into dopamine by dopa decarboxylase, increasing the concentration of dopamine in the brain, which is used to alleviate the symptoms of neurological diseases (such as Parkinson's disease). On the other hand, by delivering small nucleic acids targeting related targets of neurological diseases (such as Parkinson's disease-related targets CDK14, SNCA, LRRK2, etc.) into brain cells, neurological diseases can be improved or even solved at the gene level, bringing greater benefits to patients. Specifically, the structural formula of the compound is:
[0042] Z is C or O, X is C, N, O or S, Y is C or O, m is 1, 2 or 3, and n is 1, 2 or 3.
[0043] The inventors of the present application have conducted a lot of research and experimental effect comparison on the linker structure used to connect small nucleic acids and levodopa. The compound with a levodopa target head (L-DOPA-Mal) and the thiol group in the small nucleic acid are conjugated by click chemistry to obtain a conjugate containing small nucleic acid and levodopa. Whether the conjugate can enter brain cells is detected at the cellular level. Finally, it is found that the linker structure used in L-DOPA-Mal-1 in Example 1 (i.e., the structure of L-DOPA-Mal-1 in Example 1 after removing L-DOPA) has the best small nucleic acid delivery effect after use. The most preferred compound for delivering small nucleic acids to brain cells is:
[0044]
[0045] The technical solution, implementation process and principle will be further explained below.
[0046] The technical scheme and technical effects of the present invention are further described below in conjunction with specific embodiments and comparative examples.
[0047] Unless otherwise specified, the raw materials and the like used in the following examples were commercially available.
[0048] The small nucleic acid used in the following examples and comparative examples is a small nucleic acid targeting the SCNA gene, the sequence of the sense strand is 5'-GmsUmsAmCmAmAmGfUfGfCmUmCmAmGmUmUmCmCmAm-3', and the sequence of the antisense strand is 5'-UmsGfsGmAmAmCmUmGmAmGmCmAmCmUfUmGmUmAmCmsTsT-3'
[0049] Unless otherwise specified, the room temperature (RT) referred to in the following examples refers to 20-35° C., and the ratio of the eluents involved in the following examples is a volume ratio.
[0050] Unless otherwise specified, the experimental methods or test methods involved in the following embodiments adopt conventional methods in the art.
[0051] Example 1
[0052] Preparation and biological testing of conjugate (NDS012-01)
[0053] L-DOPA-MAL-1 Synthesis Route:
[0054]
[0055] Step 1: Synthesis of compound 2
[0056]
[0057] Dissolve 0.5 g of 11-(maleimido)undecanoic acid in 4 ml of dichloromethane (DCM), and add 1 ml of thionyl chloride (SOCl2) to the solution. Reflux in a 40°C oil bath for one hour, and then cool to room temperature. Concentrate the reaction solution to obtain a yellow crude product, which is used directly in the next step without purification.
[0058] Step 2: Synthesis of compound 3
[0059]
[0060] Dissolve 0.21 g of 3-amino-1-propanol (1.5 equivalents) in 4 ml of dichloromethane and add dropwise to a 4 ml dichloromethane solution containing the yellow crude product from the previous step and triethylamine (0.39 ml, 1.5 equivalents), and react at room temperature for 4 hours. Monitor the reaction by TLC. After the reaction is completed, add dichloromethane to dilute the reaction solution, then wash it twice with water and once with saturated brine. After the organic phase is dried over anhydrous sodium sulfate, concentrate under reduced pressure to obtain a crude product. The crude product is purified by column (dichloromethane / methanol=50 / 1) to obtain 0.23 g of the white target product, with a yield of 38%. The structure is verified:
[0061] 1H NMR(400MHz, DMSO-d6):7.73(t,J=5.2Hz,1H),7.01(s,2H),4.41(t,J=5.2Hz,1H),3.40-3. 36(m,4H),3.08-3.08(m,2H),2.02(t,J=7.2Hz,2H),1.55-1.45(m,6H),1.20-1.15(m,12H).
[0062] Chemical formula: C 18 H 30 N2O4, molecular weight: 338.22, MS[M+1] + 339.20.
[0063] Step 3: Synthesis of compound 4
[0064]
[0065] Dissolve 0.27 g of p-nitrochlorophenyl formate (1.33 equivalents) in 5 ml of dichloromethane and add dropwise to a 5 ml dichloromethane solution containing compound 3 and pyridine (0.04 ml, 0.7 equivalents). React overnight at room temperature under nitrogen protection. Monitor the reaction by TLC, and concentrate under reduced pressure to obtain a crude product after completion. The crude product is purified by column (cyclohexane / ethyl acetate = 1 / 5) to obtain 0.15 g of a white target product with a yield of 44%. The structure is verified:
[0066] 1 H NMR (400MHz, DMSO-d6): 8.32(d,J=8.8Hz,2H),7.88(t,J=5.6Hz,1H),7.56(d,J=9.2Hz,2H),7.00(s,2H),4.24(t, J=6.4Hz,2H),3.17-3.13(m,2H),2.04(t,J=7.2Hz,2H),1.83-1.77(m,2H),1.52-1.42(m,4H),1.21-1.15(m,12H).
[0067] Step 4: Synthesis of L-DAPA-Mal-1
[0068]
[0069] 40 μl (1.5 equivalents) of triethylamine was added dropwise to a 4 ml dichloromethane solution containing compound 4 (59 mg, 1.5 equivalents) and levodopa (100 mg). The reaction was allowed to proceed overnight at room temperature under nitrogen protection. The reaction was monitored by TLC, and after completion, the crude product was concentrated under reduced pressure. The crude product was purified by column (dichloromethane / methanol = 10 / 1) to obtain 21 mg of a colorless oily product (referred to as L-DOPA-MAL-1), with a yield of 19%. The structure was verified as follows:
[0070] 1 H NMR (400MHz, CD3OD): 6.69 (s, 2H), 6.57-6.55 (m, 2H), 6.45-6.43 (m, 1H), 4.20-4.19 (m, 1H), 3.93-3.91 (m, 2H), 3.37 (t, J = 7.2Hz, 2H), 3. 13-3.11(m,2H),2.94-2.90(m,1H),2.71-2.66(m,1H),2.07(t,J=7.2Hz,2H),1.69-1.63(m,2H),1.50-1.43(m,4H),1.23-1.19(m,12H).
[0071] Molecular formula: C 28 H 39 N3O9, molecular weight: 561.27, MS [M+1] + 562.30.
[0072] Chemical coupling of L-DOPA-MAL-1 and siRNA:
[0073] The obtained L-DOPA-MAL-1 was dissolved in dimethyl sulfoxide, added to the sense chain of thiol modification and fluorescent group (Cy5) (dissolved in carbonate solution), ultrasonically mixed until completely dissolved, reacted overnight at 25°C, and purified after the reaction. After that, the purified sense chain and antisense chain were equimolarly combined in PBS buffer solution to mix to form siRNA. The solution was placed in a 70°C thermal mixer, heated to 90°C, kept at 90°C for 5 minutes, and slowly cooled to room temperature to obtain a conjugate (NDS012-01).
[0074] Conjugate (NDS012-01) biological activity test:
[0075] Human neuroepithelioma cells SK-N-MC were used for testing. Cells were plated one day in advance (24-cell plate, 1.0×10 5Cells / well) were added and cells were transfected on the next day. Three groups were set up, namely NDS012-01 group (100nM siRNA), (NDS012-01 (100nM siRNA) + lipo2000) group, and blank control group (Blank, i.e. no treatment). After 24 hours of transfection, the cells were washed with serum-free medium to remove the transfected substances that did not enter the cells, and the fluorescence in the cells was observed under a fluorescence microscope. The results are shown in Figure 1 As shown, the conjugate NDS012-01 containing L-DOPA structure and siRNA can efficiently enter human neuroepithelioma cells, and the transfection effect is comparable to that after adding commercial transfection reagent (lipo2000, Invitrogen) at the same time.
[0076] Example 2
[0077] Preparation and biological testing of conjugate (NDS012-02)
[0078] L-DOPA-MAL-2 Synthesis Route:
[0079]
[0080] Step 1: Synthesis of compound 1
[0081]
[0082] Under ice bath conditions, SOCl2 (3.2 mL) was slowly added to a methanol (4 mL) solution containing L-DOPA (1 g), and the reaction solution was stirred overnight at room temperature. After the reaction was completed, the reaction solution was concentrated to obtain a crude product, which was directly used in the next reaction without purification.
[0083] Step 2: Synthesis of Compound 2
[0084]
[0085] Compound 1 (0.57 g, crude product) and Boc-aminocaproic acid (0.75 g) were dissolved in 10 mL DMF, HBTU (1.3 g) and DIPEA (0.47 mL) were added, and the reaction solution was stirred at room temperature overnight under nitrogen protection. The reaction solution was then concentrated and dissolved in ethyl acetate, washed with 0.1 M HCl solution and saturated brine. The organic phase was dried and concentrated and then purified by column (DCM: MeOH = 30: 1) to obtain 0.66 g of colorless oil 2.
[0086] Step 3: Compound 3
[0087]
[0088] Trifluoroacetic acid (2 mL) was added dropwise to a solution of 0.44 g of compound 2 in dichloromethane (4 mL), and the mixture was stirred for half an hour at room temperature under nitrogen protection. The reaction solution was then concentrated to obtain a crude yellow oil 3.
[0089] Step 4: Synthesis of compound 4
[0090]
[0091] Compound 3 (crude product) and DIPEA (0.35 mL) were dissolved in 10 mL DMF, 11-(maleimido) undecanoic acid succinimide ester (0.41 g) was added, and the reaction solution was stirred at room temperature overnight under nitrogen protection. The reaction solution was then concentrated and dissolved in ethyl acetate, washed with 0.1 M HCl solution and saturated brine. The organic phase was dried and concentrated and then column purified (DCM: MeOH = 50: 1) to obtain 450 mg of colorless oil 4. The structure was confirmed as shown in Figure 2 .
[0092] Step 5: Synthesis of Compound 5 (i.e. L-DOPA-Mal-2)
[0093]
[0094] 5 mL of 6N HCl solution was added to the acetone solution (10 mL) of compound 4, and the mixture was stirred overnight at room temperature under nitrogen protection. The reaction solution was then concentrated and dissolved in ethyl acetate, washed with 0.1 M HCl solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain 0.3 g of yellow oily compound 5. The structure was confirmed as shown in Figure 3 , denoted as L-DOPA-Mal-2.
[0095] Chemical coupling of L-DOPA-MAL-2 and siRNA:
[0096] The obtained L-DOPA-MAL-2 (compound 5 in the previous step) was dissolved in dimethyl sulfoxide, added to the small nucleic acid modified with thiol and containing a fluorescent group (Cy5) (dissolved in carbonate solution), ultrasonically mixed until completely dissolved, reacted at 25°C overnight, and purified after the reaction. After that, the sense chain and the antisense chain were mixed in PBS buffer solution in equal moles to form siRNA. The solution was placed in a 70°C thermomixer, heated to 90°C, kept at 90°C for 5 minutes, and slowly cooled to room temperature to obtain a conjugate (NDS012-02).
[0097] Comparative test of biological activity of conjugate (NDS012-02) and conjugate (NDS012-01):
[0098] Human neuroepithelioma cells SK-N-MC were used for testing. Cells were plated one day in advance (24-cell plate, 1.0×10 5 Cells / well), and cell transfection was performed on the next day. Five groups were set up, namely NDS012-02 group (200nM siRNA), (NDS012-02 (200nM siRNA) + lipo2000) group, NDS012-01 group (200nM siRNA), (NDS012-01 (200nM siRNA) + lipo2000) group, and blank control group (Blank, i.e., no treatment). After 24 hours of transfection, the transfected substances that did not enter the cells were washed with serum-free medium, and the fluorescence in the cells was observed under a fluorescence microscope. The results are shown in Figure 4 As shown, compared with the conjugate NDS012-01, the conjugate NDS012-02 containing L-DOPA structure and siRNA can enter into human neuroepithelioma cells to a small extent without adding commercial transfection reagent (lipo2000, Invitrogen).
[0099] Comparative Example 1
[0100] Preparation and biological testing of conjugate (NDS012-03)
[0101] L-DOPA-MAL-3 synthesis route:
[0102]
[0103] Step 1: Synthesis of compound 1
[0104] In an ice bath, SOCl2 (3.2 mL) was slowly added to a solution of L-DOPA (1 g) in methanol (4 mL), and the mixture was heated to room temperature and stirred overnight. After the reaction, the reaction solution was concentrated to obtain a crude product, which was directly used in the next step without purification.
[0105] Step 2: Synthesis of Compound 2
[0106]
[0107] HBTU (0.88 g) and DIPEA (0.31 mL) were added to a DMF (10 mL) solution containing compound 1 (0.57 g, crude product) and 11-(maleimido)undecanoic acid (0.5 g), and the reaction solution was stirred at room temperature overnight under nitrogen protection. The reaction solution was concentrated and dissolved in ethyl acetate, and washed with 0.1 M HCl solution and saturated brine. The organic phase was dried and concentrated and then purified by column (DCM: MeOH = 30: 1) to obtain 0.5 g of colorless oily compound 2. The structure was confirmed as shown in Figure 5 .
[0108] Step 3: Synthesis of Compound 3 (i.e. L-DOPA-Mal-3)
[0109]
[0110] 6N HCl (5 mL) was added to a solution of compound 2 (0.4 g dissolved in 10 mL acetone), and the reaction solution was stirred at room temperature overnight under nitrogen protection. The reaction solution was concentrated and dissolved in ethyl acetate, washed with 0.1 M HCl solution and saturated brine, and the organic phase was dried over anhydrous sodium sulfate and concentrated to obtain 0.3 g of yellow oily compound 3. The structure was confirmed as shown in Figure 6 , denoted as L-DOPA-MAL-3.
[0111] Chemical coupling of L-DOPA-MAL-3 and siRNA:
[0112] The obtained L-DOPA-MAL-3 (compound 3 in the previous step) was dissolved in DMSO, added to the small nucleic acid modified with thiol and containing a fluorescent group (FAM) (dissolved in carbonate solution), ultrasonically mixed until completely dissolved, reacted overnight at 25°C, and purified after the reaction. After that, the sense chain and the antisense chain were mixed in PBS buffer solution in equal moles to form siRNA. The solution was placed in a 70°C thermomixer, heated to 90°C, kept at 90°C for 5 minutes, and slowly cooled to room temperature to obtain a coupling product (NDS012-03).
[0113] Comparative test of biological activity of conjugate (NDS012-03) and conjugate (NDS012-01):
[0114] Human neuroepithelioma cells SK-N-MC were used for testing. Cells were plated one day in advance (24-cell plate, 1.0×10 5 cells / well), and cell transfection was performed on the next day. Five groups were set up, namely NDS012-03 group (100 nM siRNA),
[0115] (NDS012-03 (100nM siRNA) + lipo2000) group, NDS012-01 group (100nM siRNA), (NDS012-01 (100nM siRNA) + lipo2000) group, and blank control group (Blank, i.e., no treatment). After 24 hours of transfection, the cells were washed with serum-free medium to remove the transfected material that did not enter the cells, and the fluorescence in the cells was observed under a fluorescence microscope. The results are shown in Figure 7 As shown, compared with the conjugate NDS012-01, the conjugate NDS012-03 containing L-DOPA structure and siRNA cannot enter into human neuroepithelioma cells without adding commercial transfection reagent (lipo2000, Invitrogen).
[0116] In vivo experiments:
[0117] Using 6-7 week old C57BL / 6J mice, a single intrathecal administration (10 μg) of NDS012-01 of Example 1 was performed, and NDS012-03 of Comparative Example 1 was set as a control group, and a normal mouse group (only injected with saline) was set as a blank control group to study the distribution of the coupled drug after intrathecal injection and the expression of the target gene (SCNA gene). The specific test items are as follows:
[0118] IVIS imaging detection: 0.1mL of Zotai 50 anesthetic was injected intraperitoneally for every 10g of the mouse's body weight. After waiting for 5 minutes, the mouse was placed in a small animal live imaging instrument for imaging; for tissue imaging observation, the mouse was killed, and each tissue (including spinal cord, brain, heart, liver, spleen, lung, and kidney) was dissected and placed in the imaging instrument. The imaging channel was set to Cy3 (550nm, 570nm) corresponding to the excitation and emission wavelengths. After imaging, the fluorescence intensity data (mouse live imaging and each tissue) were statistically analyzed. The fluorescence of the experimental group (NDS012-01) was mainly distributed in the spinal cord and brain at the injection site.
[0119] Drug residue detection: At the end of the experiment of each group of mice, brain tissues (cerebellum, brainstem, temporal cortex, frontal cortex, hippocampus) and spinal cords (cervical, thoracic, lumbar segments) were taken and homogenized, and quality control samples and standards were prepared at the same time. Then SL-QPCR was performed to detect the siRNA residues in brain tissues and spinal cords. The experimental group (NDS012-01) had relatively more residues in brain tissues and lumbar segments at the injection site.
[0120] Target gene detection: At the end of the experiment, the brain tissues of each group of mice (cerebellum, brainstem, temporal cortex, frontal cortex, hippocampus) and spinal cord (cervical, thoracic, lumbar segments) were taken to extract RNA from each tissue, and then RT-PCR was used to detect the mRNA expression of target genes. In the brain, dopamine mainly acts through the nigrostriatal pathway and the midbrain cortical pathway. The experimental group (NDS012-01) can target and silence the expression levels of target genes in tissues such as the brainstem, temporal cortex, frontal cortex and hippocampus.
[0121] Although the present invention describes certain embodiments of compounds capable of delivering small nucleic acids to brain cells, methods for preparing the compounds, and conjugates with small nucleic acids, and many details have been described for illustrative purposes, the embodiments of the present invention are not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the scope of protection of the present invention.
Claims
1. A compound for delivering small nucleic acids to brain cells, Features: The structural formula of the compound is: Z is C or O, X is C, N, O or S, Y is C or O, m is 1, 2 or 3, and n is 1, 2 or 3.
2. The compound for delivering small nucleic acids to brain cells according to claim 1, Features: The X is O or C, the Y is C, and the Z is C; And / or, m is 1 or 2, and n is 1 or 2.
3. The compound for delivering small nucleic acids to brain cells according to claim 1, Features: The compound is:
4. Use of the compound for delivering small nucleic acids to brain cells according to any one of claims 1 to 3 in the preparation of targeted drugs for preventing or treating nervous system diseases.
5. The use according to claim 4, It is characterized in that The nervous system disease includes Parkinson's disease, and the effective ingredient of the targeted drug includes a small nucleic acid, which is a small nucleic acid that can target and inhibit the expression of target points related to nervous system diseases.
6. A conjugate, It is characterized in that The conjugate is formed by chemically coupling a small nucleic acid capable of targeted inhibition of expression of a target site associated with a nervous system disease and the compound for delivering the small nucleic acid to brain cells according to any one of claims 1 to 3.
7. The conjugate according to claim 6, It is characterized in that The preparation method of the conjugate is: mixing a thiol-modified small nucleic acid sequence with the compound for delivering small nucleic acids to brain cells described in any one of claims 1 to 3 at 20-30° C. to obtain the conjugate.
8. The conjugate according to claim 7, It is characterized in that The small nucleic acid is siRNA, and the sense strand of the siRNA is mixed with the compound for delivering the small nucleic acid to brain cells to obtain a conjugate, and then the sense strand and the antisense strand are mixed in equimolar amounts to form a conjugate containing a L-DOPA structure and siRNA.
9. The use according to claim 4 or the conjugate according to claim 6, wherein the target related to nervous system diseases comprises one or more of CDK14, SNCA or LRRK2; And / or, the small nucleic acid includes one or more of a messenger nucleic acid, a small interfering nucleic acid, a micronucleic acid, a small activating nucleic acid, an antisense oligonucleotide or an aptamer.
10. A targeted drug for preventing or treating a nervous system disease, It is characterized in that The targeted drug comprises the conjugate according to any one of claims 6 to 9, optionally comprising a pharmaceutically acceptable excipient.
Citation Information
Patent Citations
Cytotoxic peptides and antibody drug conjugates thereof
CN104185477A
Prophylactic and / Or therapeutic agent of parkinson'S disease
JP2002097137A
